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Testosterone treatment induces erythrocytosis that could potentially affect blood viscosity and
cardiovascular risk. We thus investigated the effects of testosterone administration on blood vis-
cosity and erythrocyte deformability using mouse models. Blood viscosity, erythrocyte deform-
ability, and hematocrits weremeasured in normal male and femalemice, as well as in females and
castratedmales after short-term (2-weeks) and long-term (5 –7months) testosterone intervention
(50 mg/kg, weekly). Castrated males for long-term intervention were studied in parallel with the
normal males to assess the effect of long-term testosterone deprivation. An additional short-term
intervention studywas conducted in femaleswith a lower testosterone dose (5mg/kg). Our results
indicate no rheological difference among normal males, females, and castrated males at steady-
state. Short-term high dose testosterone increased hematocrit and whole blood viscosity in both
females and castratedmales. This effect diminished after long-term treatment, in associationwith
increased erythrocyte deformability in the testosterone-treated mice, suggesting the presence of
adaptive mechanism. Considering that cardiovascular events in human trials are seen early after
intervention, rheological changes as potential mediator of vascular events warrant further
investigation.
The use of testosterone as a prescription drug has in-creased dramatically in recent years. Several studies
raised concerns about the cardiovascular risk of testoster-
one therapy (1–3). Epidemiologic studies suggested that
both very low and very high testosterone levels are linked
to cardiovascular and cerebral risk (4, 5), but the mech-
anism remains unclear. Elevated blood viscosity is asso-
ciated with cardiovascular and cerebral risk, especially in
the context of therapeutic administration of erythropoie-
sis-stimulating agents (6–9). Likewise, testosterone ad-
ministration consistently increases hematocrits in men
(10, 11). Because erythrocyte mass is a major contributor
to blood viscosity, testosterone administration might thus
increase blood viscosity. However, relevant literature is
scant and inconclusive (12–14). On the other hand, in-
creased erythrocyte deformability has been reported in
erythropoietin-transgenic mice, which allows the mice to
offset their whole blood viscosity to a much lower level
than that predicted from their exceptionally high hemat-
ocrits (15). It is unclear whether men or animals acquire
similar adaptations to testosterone-induced erythrocyto-
sis. Herein we report the effects of testosterone on blood
viscosity and erythrocyte deformability in mice after
short-term and long-term interventions.
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Materials and Methods
1. Animals. For long-term intervention experiments, precas-
trated male, sham male and female C57BL/6 mice were pur-
chased from Jachson laboratory (Bar Harbor, ME) at six weeks
of age. For short-term experiments, precastrated male and fe-
male mice were purchased as retired breeders (7 – 8 months). At
the end point, all mice were about 8–9 months. Mice were ran-
domized to vehicle or testosterone groups with matching levels
of hematocrits at baseline. Testosterone propionate was injected
subcutaneous weekly at 50 mg/kg in 100 l medium-chain tri-
glyceride oil (www.Life-enhancement.com) for either 2 weeks
(females and castrated males) or 5 months (females) and 7
months (castrated males). In response to the reviewers’ sugges-
tion, additional female mice were tested with low dose testos-
terone propionate (5 mg/kg). All control mice were weekly in-
jected with 100 ul vehicle oil. The number of animals for each
experiment is listed in the corresponding figure legend. All mice
were housed in the Center for Animal Resources at Harvard
Medical School with controlled temperature at 21°C and 12/12
light/dark cycle with free access to water and standard chow. The
use of animals was approved by the IACUC of Harvard Medical
School.
2. Blood analysis. Erythrocyte packing difference (EPD) was
measured as a marker for erythrocyte sedimentation rate (ESR)
(16). Briefly, a microhematocrit tube was filled with tail-vein
blood and spun at 100g x 30 at room temperature for the ap-
parent hematocrit reading. Then the same tube was spun in
CritSpin (Iris Sample Processing, Inc. MA) to obtain the standard
hematocrit reading. EPD was calculated as the difference be-
tween these two readings.
Complete blood counts were obtained from the Hematology
Core at Boston Children’s Hospital (Boston, MA). Blood vis-
cosity was measured as described (15). Blood was obtained via
cardiac puncture into an EDTA blood collection tube and ana-
lyzed within 5 – 10 minutes using a rotation viscosimeter (DVIII_
Rheometer, Brookfield Engineering Laboratories, Middleboro,
MA). Viscosity was recorded at 37°C under different shear rates.
Plasma viscosity was analyzed similarly except that samples were
prestored at –80°C. Erythrocyte deformability was measured as
the elongation rate (15). Whole blood (0.3 ml) was mixed with
3 ml of phosphate-buffered saline (PBS) containing 14.4% Dex-
tran (#D6030, USbiological, MA) with a viscosity of 10 mPas,
close to human peripheral artery blood viscosity at low shear rate
(17). For selected experiments, a high viscosity Dextran solution
was also tested (24 mPas). The osmolarity of both solutions was
adjusted to 310–320 mOsm/kg. The erythrocyte suspension was
used to measure erythrocyte elongation rate using a Laser dif-
fractometer (Rheodyn-SSD; Myrenne, Ro˝ttgen, Germany).
Serum testosterone was measured using LC-MS/MS, an assay
certified by the Hormone Assay Standardization Program of
CDC as described previously (18). Because of the small volume
available from some animals, serum samples were pooled for
some analyses. Serum testosterone were undetectable ( 0.01
ng/mL) in vehicle-treated castrated males and increased with
testosterone treatment (9.3  3.4 ng/ml, mean  SD, n  5,
pooled plasma from 13 animals). Testosterone levels were also
elevated in testosterone-treated females (7.1  3.0 ng/ml and
0.88  0.37 ng/ml for high- and low-dose testosterone, respec-
tively, n7 for the low dose group, n3, pooled from 8 animals
for the high dose group), as compared to that in vehicle-treated
females (0.04  0.13 ng/mL, n  15). The mean testosterone
level in normal males was 0.57  0.66 ng/ml. Thus, high-dose
testosterone administration in females and castrated males re-
sulted in supra-physiologic testosterone levels whereas low-dose
treatment in females resulted in a level close to that in normal
adult males.
Because pharmacokinetics of testosterone are characterized
by peaks of testosterone levels shortly after injection followed by
gradual decline over the ensuing dosing interval, we obtained
additional samples to assess the time-dependent changes in se-
rum testosterone after injection. As displayed in Supplemental
Figure s1, serum testosterone declines rapidly after reaching a
peak. Effects of treatment on kidney and spleen weights are
shown in Supplemental Table s1; kidney mass, but not spleen,
responded to testosterone treatment, as expected (19).
3. Statistics. Statistical analyses were performed using SAS 9.3
software (SAS Institute, Cary NC) and Prism software (Graph-
Pad Software Inc.). Results are shown as mean  SD. For he-
matological parameters, comparison between the vehicle- vs tes-
tosterone-treated groups (and nontreated females vs nontreated
males) were done using t test for independent samples and paired
comparisons. For blood viscosity and erythrocyte elongation
rate, analysis of variance (ANOVA) with repeated measures was
performed. To assess the interaction between main effect and
shear force (or shear rate), Mauchly’s sphericity test was per-
formed and Greenhouse-Geisser adjusted p-values were calcu-
lated. If the interaction was found to be nonsignificant, overall
main effect was tested. For each shear force (rate), t test for main
effects was also performed. Statistical significance was evaluated
at 0.05 level of alpha.
Results
1. Comparison between normal male and female
mice
The RBC indices were generally similar between male
and female mice with a trend towards higher hematocrit
level in the males (Table s2a). Females had higher reticu-
locyte count but lower mean corpuscular volume (MCV)
than males. EPD was higher in the males than the females
(6.5  1.1% vs 4.0  0.8%, P  .01), replicating the
findings in humans (16). No sex difference was detected in
whole blood viscosity and plasma viscosity (Figure 1A-B).
Female mice showed slightly higher erythrocyte deform-
ability at high shear forces (Figure 1C&D), as would be
predicted by their higher reticulocyte counts (Table s2a).
2. Effect of short-term testosterone treatment in
female and castrated male mice
Testosterone treatment at high dose (50 mg/kg) for two
weeks increased hematocrits (Figure 2A) and EPD (Figure
2B) in female mice. Expected increase in other RBC indices
were also observed (not shown), as we had recently re-
ported (20). This treatment was associated with higher
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whole blood viscosity (Figure 2C). A maximal increase of
approximately 13% was observed at 15s-1, a shear rate
that falls in the diastolic range (7). The difference became
smaller but remained significant at higher shear rates in the
systolic range also (Figure 2C). Plasma viscosity (Figure
2D) was not different between the two groups. An increase
in erythrocytes deformability was detected in testoster-
one-treated females but only at the highest shear force
tested (Figure 2E). Similarly, short-term testosterone
treatment at the same high dose increased hematocrits in
castrated male mice (Supplemental Figure s2A), EPD (Fig-
ure s2B), and other RBC indices (Table s2b), in association
with an increase in whole blood viscosity (Figure s2C) but
with no effect on plasma viscosity (Figure s2D) and eryth-
rocyte deformability (Figure s2E).
In contrast, when female mice were treated with a low
dose testosterone (5 mg/kg) for two weeks, there was no
detectable change in blood viscosity (Figure s3A) and
erythrocyte deformability (Figure s3B). Short-term treat-
ment with low dosage did not affect hematocrit and other
RBC indices (Table s2c), as previously reported (21), but
this dose still increased kidney weight moderately (Table
s1c).
3. Effect of long-term testosterone treatment on
female and castrated male mice
During prolonged intervention (5–7 months) with high
dose testosterone, serum testosterone levels remained el-
evated at supra-physiologic levels. In female mice, hema-
tocrits returned to baseline and did not differ between
vehicle- and testosterone-treated groups (Figure 3A). EPD
was not different between the two groups (not shown).
Other RBC indices were similar except that testosterone-
treated group had higher RDW and MCV (Table s2d).
Plasma viscosity and whole blood viscosity were not dif-
ferent (Figure 3B-C). However, erythrocyte deformability
was significantly increased in the testosterone-treated
group (Figure 3D). In castrated male mice, hematocrits
remained about 2% higher in the testosterone-treated
group (Figure s4A), which also had higher values for
MCV, RDW, and CHr (Table s2e). Importantly, pro-
longed administration of high dose testosterone did not
negatively affect plasma and whole blood viscosity in cas-
trated males (Figure s4B-C) but increased the erythrocyte
deformability (Figure s4D).
We also compared the intact males and long-term cas-
trated males and found no significant effect of prolonged
testosterone deprivation on whole blood viscosity and
erythrocyte deformability (Figure s5).
Discussion
The increased clinical use of testos-
terone in hypogonadal men, as well
as its consistent effect of erythrocy-
tosis with its controversial cardio-
vascular risks, argues for a need to
better understand the rheological ef-
fect of testosterone. To our knowl-
edge, this is the first study to com-
prehensively assess the effects of
testosterone on whole blood and
plasma viscosity, erythrocyte de-
formability, and to compare sex dif-
ferences after short-term as well as
longer-term treatments. Our results
indicate that long-term intervention
did not adversely affect whole blood
viscosity and plasma viscosity in
adult mice supplemented to supra-
physiologic levels of testosterone. In
contrast, short-term administration
of high dose testosterone transiently
raised whole blood viscosity in asso-
ciation with increased hematocrits in
Figure 1. Whole blood viscosity, plasma viscosity, erythrocyte deformability in
adult mice. Adult male and female mice were studied without intervention: (A) whole blood
viscosity, (B) plasma viscosity, (C) erythrocyte deformability (elongation rate) at near physiological
viscosity (10 mPas), (D) erythrocyte elongation rate at supra-physiological viscosity (24 mPas). M:
male, F: females. Results are shown as mean  SD, n  8 – 12 mice in each group, pm: main
effect, pi: interactions,
# P  .05, ## P  .01, ### P  .001, t test.
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female and castrated male mice. At shear rate of 15 sec-
onds-1, whole blood viscosity was increased by 13% and
15% for females and castrated males, respectively. Al-
though moderate, such an effect may increase risk for ad-
verse clinical outcomes in subjects with comorbidities
(22). Importantly, our data suggest the presence of adap-
tive mechanisms that restored whole blood viscosity to
normal during prolonged testosterone administration.
The effect of short-term administration of high dose
testosterone on whole blood viscosity was associated with
the expected increase in hematocrits at this time point.
Although hematocrits is a determinant of whole blood
Figure 2. Effect of short-term testosterone treatment in female mice. Adult female mice were injected weekly with vehicle or
testosterone propionate (50 mg/kg) for two weeks and measured for: (A) hematocrits, (B) erythrocyte packing difference (EPD), (C) whole blood
viscosity, (D) plasma viscosity, measured at shear rate of 172s-1, (E) erythrocyte elongation rate. F: females on vehicle, FT: females treated with
testosterone. Results are shown as mean  SD, n  8 – 12, pm: main effect, pi: interactions, ** P  .01, paired t test,
# P  .05, ## P  .01, ###
P  .001, unpaired t test.
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viscosity, its contribution is considered important at high
shear rates, whereas erythrocyte aggregation and plasma
factors are thought to be important determinants at low
shear rates (7, 9). However, no testosterone effect on
plasma viscosity was found during this work. Although we
didnotdirectlymeasure erythrocyteaggregation,we show
that EPD was increased after short-term high dose testos-
terone treatment in both females and castrated males, sug-
gesting that erythrocytes in these mice were more buoyant
and thus less likely to form shear-resistant aggregates, in
agreement with the predicted increase of young erythro-
cytes (20, 23). Hence, a mechanism to explain the increase
of blood viscosity after short-term high dose testosterone
intervention remains unclear, if due to factors other than
the obvious increase in hematocrits.
In agreement with the well-known sex differences that
men have higher hematocrits and lower RDW than
women (24), we recorded a slightly higher hematocrit in
male mice than in female mice, although the difference did
not reach statistical significance. Adult men generally have
higher blood viscosity and greater erythrocyte fragility
than women of reproductive age. We do not know
whether this is due to regular blood renewal in women or
the testosterone effect in men (25). However, we did not
detect a difference in blood viscosity or erythrocyte de-
formability between adult male and female mice, which,
unlike women, do not experience menstrual blood loss.
The mechanism of sex differences in hematocrit and blood
viscosity in humans is not entirely clear. It is possible that
the estrogens may have independent effects on erythro-
poiesis. Estradiol has been shown to directly affect lym-
phopoiesis and osteoclasts (which are of hematopoietic
origin (26)) but it has not been shown to directly affect
erythropoiesis or erythrocyte survival. Studies of men with
aromatase deficiency suggest that testosterone’s conver-
sion to estradiol is not required for mediating its effects on
erythropoiesis and that estradiol does not significantly he-
moglobin and hematocrit (27). It is therefore likely that the
narrowing of the sex difference in hemoglobin and hemat-
ocrit after menopause is at least in part due to the cessation
of menstrual blood loss in women.
The apparent lack of difference shown in Figure 1 sug-
gests, but does not prove, that testosterone per se has no
negative effect on blood viscosity and erythrocyte deform-
ability. This argument is also supported by the observation
that long-term deprivation of testosterone in male mice
did not elicit detectable improvement in blood viscosity or
erythrocyte deformability compared to normal males.
Furthermore, long-term treatment with supra-physiologic
testosterone did not elicit detectable adverse perturbations
to blood viscosity in both females and castrated males.
Interestingly, erythrocyte deformability was increased af-
ter long-term high dose testosterone treatment. Whether
the increase in erythrocyte deformability was a direct ef-
fect of testosterone on erythrocytes remains to be inves-
tigated. It was recently reported that testosterone replace-
ment in castrated prostate cancer
patients improves erythrocyte mem-
brane lipid profile (28), an effect that
would predict improved erythrocyte
deformability (9). Since erythrocyte
lifespan is typically 45–50 days in
adult mice (29), most of the circulat-
ing erythrocytes tested in the short-
term experiments were formed be-
fore testosterone intervention. After
months of treatment, all circulating
erythrocytes were formed under su-
pra-physiological levels of testoster-
one. This may play a role to allow
detection of the small changes in
erythrocyte deformability.
Our study has notable strengths
and limitations. We performed a
comprehensive assessment of the
rheological effect in female and cas-
trated male mice after both short-
term and long-term testosterone in-
terventions. The testosterone dosage
clearly raised the circulating testos-
Figure 3. Effect of long-term testosterone treatment in female mice. Female mice
were treated weekly with testosterone propionate (50 mg/kg, sc) for 5 months and measured
for: (A) hematocrits, (B) plasma viscosity, (C) whole blood viscosity, and (D) erythrocyte
deformability. F: females on vehicle, FT: females treated with testosterone. Results are shown are
mean  SD, n  12 –14 per group, pm: main effect, pi: interactions,
#P  .05, ##P  .01, t test.
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terone concentrations into the supra-physiologic range.
These studies were conducted in healthy adult mice.
Hence, the relevance to aged and diseased individuals re-
mains to be investigated. In addition, we used intact female
mice for this work. While this has the advantage for as-
sessing the physiologically relevant sex difference, treat-
ment with exogenous testosterone could potentially dis-
turb ovarian cycling and estrogen production. How this
may contribute to the observations also remains to be
studied. In summary, although short-term administration
of high dose testosterone increased whole blood viscosity
in association with increased hematocrits, the effects did
not sustain long-term interventions.Additionalpreclinical
studies using older animals with comorbidities, as well as
clinical trials, are required to further define the rheological
effect of testosterone supplementation and their conse-
quences in men, especially those with coronary artery dis-
ease (CAD).
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